Search | Clinical Trials Finder

Conditions: Interstitial Cystitis, Bladder Pain Syndrome
Interventions: Heparin & Alkalinized Lidocaine Bladder Instillation, Onabotulinum Toxin A; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Non-Hodgkin's Lymphoma
Interventions: CHOP, Alemtuzumab, Plasma Samples; Drug · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Diabetes Type 2
Interventions: Vitamin E, Vitamin C; Dietary Supplement
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, de Novo Myelodysplastic Syndrome, High Risk Myelodysplastic Syndrome, Inv(16), Myelodysplastic Syndrome With Excess Blasts, t(16;16), t(8;21), Untreated Adult Acute Myeloid Leukemia
Interventions: Cytarabine, Decitabine, Filgrastim-sndz, Fludarabine Phosphate, Gemtuzumab Ozogamicin, Idarubicin, Laboratory Biomarker Analysis; Drug · Biological · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myeloid Leukemia
Interventions: Cytarabine, Idarubicin, Omacetaxine mepesuccinate; Drug
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Post Traumatic Stress Disorder
Interventions: Iloperidone, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy Participants
Interventions: LOAM, Inulin, Cellulose Placebo; Dietary Supplement
Lead sponsor: Ventoscity LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Sarcopenia, Aging
Interventions: powdered egg white protein supplement, maltodextrin supplement; Dietary Supplement
Lead sponsor: The University of Texas at San Antonio; Other
Eligibility: 60 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Endometrial Cancer
Interventions: filgrastim, cisplatin, doxorubicin hydrochloride, paclitaxel; Biological · Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 59 more

Conditions: Hematologic Malignancies
Interventions: Granulocyte Colony Stimulating Factor; Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 22 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Fibrolamellar Hepatocellular Carcinoma, Hepatocellular Carcinoma (Fibrolamellar Variant), Hepatocellular Carcinoma
Interventions: living related donor partial liver transplantation, Total body irradiation, Bone marrow transplant from same donor, Cyclophosphamide, Mesna, Filgrastim, Tacrolimus, mycophenolate mofetil, Prednisone, Antithymocyte globulin, fludarabine; Procedure · Radiation · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 16 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes, PreDiabetes, Metabolic Disease, Hyperglycemia, Diet Modification, Glucose Intolerance, Glucose Metabolism Disorders (Including Diabetes Mellitus), Endocrine System Diseases
Interventions: Low-Carbohydrate Diet; Behavioral
Lead sponsor: Tulane University School of Public Health and Tropical Medicine; Other
Eligibility: 40 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Lung Cancer Stage II, Lung Cancer Stage III, Non Small Cell Lung Cancer
Interventions: SBRT, Carboplatin, Paclitaxel, cis Platinum, Etoposide, IMRT, Durvalumab; Radiation · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Neuroepithelial Tumor, Solid Tumor, Allogeneic Hematopoietic Stem Cell Transplantation
Interventions: Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy, Keratinocyte Growth Factor, Alemtuzumab, Thiotepa, Etoposide, Fludarabine, Melphalan, Tacrolimus, Cyclosporine A, Mycophenolate mofetil; Procedure · Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: Up to 60 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Anaplastic Medulloblastoma, Medulloblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Leucovorin Calcium, Methotrexate, Quality-of-Life Assessment, Thiotepa, Vincristine Sulfate; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 2 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2025
U.S. locations: 129
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 100 more

Conditions: Acute Lymphoblastic Leukemia
Interventions: Inotuzumab ozogamicin, Methotrexate, Hydrocortisone, Cytarabine, Diphenhydramine, Acetaminophen, Methylprednisolone; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: San Diego, California • Memphis, Tennessee

Conditions: Graft Versus Host Disease
Interventions: GLASSIA, methylprednisolone or equivalent steroid, Albumin; Biological · Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Breast Cancer
Interventions: Grape Seed Extract; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 55 Years to 75 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Gastroesophageal Reflux Disease, Chronic Insomnia
Interventions: Rozerem (ramelteon), placebo; Drug
Lead sponsor: Southern Arizona VA Health Care System; Federal
Eligibility: Up to 82 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Inulin, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration; Procedure · Dietary Supplement · Biological + 1 more
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Inflammation, Oxidative Stress, Resistance Exercise, Recovery, Exercise Performance Recovery
Interventions: Haskap berry smoothie, Placebo Comparator; Dietary Supplement
Lead sponsor: Montana State University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: Bladder Cancer
Interventions: personalized ultrafractionated stereotactic ablative radiotherapy; Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Adverse Pregnancy Outcome
Interventions: Lovenox 40mg; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Evanston, Illinois

Search by objective public record fields.

Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas

Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients

Iloperidone for Symptoms of Arousal in Post Traumatic Stress Disorder (PTSD)

Comparing Prebiotic Fiber Supplements for Gut Health and Digestive Comfort

Supplemental Egg Protein Intervention in Older Adults

Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome

Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)

Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors

Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD

The Effect of Grape Seed Extract on Estrogen Levels of Postmenopausal Women

Effect of Rozerem on the Perception of GERD Symptoms in Patients With Chronic Insomnia.

Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

Impact of Haskap Berries on Recovery From High Intensity Resistance Training

Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer

Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project